TEVA-DORZOTIMOL 5 MG — DIN 02320525
TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG · TEVA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is TEVA-DORZOTIMOL?
TEVA-DORZOTIMOL 5 MG contains TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02320525, held by TEVA CANADA LIMITED, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as cancelled post market, status dated 19-Jun-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is TEVA-DORZOTIMOL used for?
Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Timolol, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
23 holders have a Canadian DIN containing Timolol, Combinations, across 50 DINs, of which 21 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 5 | 4 | DORZOLAMIDE-TIMOLOL, JAMP BRIMONIDINE/TIMOLOL, JAMP DORZOLAMIDE-TIMOLOL, JAMP-LATANOPROST/TIMOLOL, LATANOPROST / TIMOLOL | Sourceable in Canada |
| APOTEX INC | 5 | 3 | APO-BRIMONIDINE-TIMOP, APO-DORZO-TIMOP, APO-LATANOPROST-TIMOP, APO-TRAVOPROST-TIMOLOL PQ, APO-TRAVOPROST-TIMOP PQ | Sourceable in Canada |
| ELVIUM LIFE SCIENCES | 2 | 2 | COSOPT, COSOPT PRESERVATIVE-FREE | Sourceable in Canada |
| GENERIC MEDICAL PARTNERS INC | 2 | 2 | MED-DORZOLAMIDE-TIMOLOL, MED-LATANOPROST-TIMOLOL | Sourceable in Canada |
| MANTRA PHARMA INC | 2 | 2 | M-DORZOLAMIDE-TIMOLOL, M-LATANOPROST-TIMOLOL | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 2 | 2 | AZARGA, DUOTRAV PQ | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 1 | SANDOZ BRIMONIDINE / TIMOLOL, SANDOZ DORZOLAMIDE/TIMOLOL, SANDOZ LATANOPROST/TIMOLOL, SANDOZ TRAVOPROST / TIMOLOL PQ | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 1 | ACT DORZOTIMOLOL, TEVA-DORZOTIMOL, TEVA-LATANOPROST-TIMOLOL, TEVA-LATANOPROST/TIMOLOL | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 3 | 1 | MYLAN-DORZOLAMIDE/TIMOLOL, MYLAN-LATANOPROST/TIMOLOL | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 1 | RIVA-DORZOLAMIDE/TIMOLOL, RIVA-LATANOPROST/TIMOLOL | Sourceable in Canada |
| ABBVIE CORPORATION | 1 | 1 | COMBIGAN | Sourceable in Canada |
| BGP PHARMA ULC | 1 | 1 | XALACOM | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
| Pack configuration (monograph) | Plastic bottle dispensers containing 5 mL and 10 mL. |
| Storage | Store at 15°C - 25°C (59°F - 77°F). Protect from light. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Timolol, Combinations |
|---|---|
| ATC code | S01ED51 |
| AHFS class | 52:40.12 ; 52:40.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02320525 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2320525 |
| Brand name | TEVA-DORZOTIMOL |
| Generic / active ingredient | TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | S01ED51 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01ED |
| Current status | CANCELLED POST MARKET |
| Status date | 19-Jun-2018 |
| Original market date | 2010-12-08 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
One drop in the affected eye(s) two times daily. If using multiple topical ophthalmic drugs, administer at least ten minutes apart.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; bronchospasm, asthma, COPD; sinus bradycardia, AV block, cardiac failure, cardiogenic shock; severe renal impairment (CrCl < 0.5 mL/s); oral carbonic anhydrase inhibitors.
Warnings and precautions
Systemic absorption may occur; potential for severe sulfonamide/beta-blocker reactions (e.g. Stevens-Johnson). Caution in diabetes, cardiac disease, and patients with corneal abnormalities.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
21 of 50 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BRIMONIDINE-TIMOP | 0.5 % | SOLUTION | APOTEX INC | MARKETED | 02375311 |
| APO-DORZO-TIMOP | 5 MG | SOLUTION | APOTEX INC | MARKETED | 02299615 |
| APO-TRAVOPROST-TIMOP PQ | 0.5 % | SOLUTION | APOTEX INC | MARKETED | 02415305 |
| AZARGA | 0.5 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02331624 |
| COMBIGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | 02248347 |
| COSOPT | 5 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | 02240113 |
| COSOPT PRESERVATIVE-FREE | 20 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | 02258692 |
| DORZOLAMIDE-TIMOLOL | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02522020 |
| DUOTRAV PQ | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02278251 |
| JAMP BRIMONIDINE/TIMOLOL | 0.2 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02531704 |
2 · Same class — other molecules in ATC S01ED
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Timolol, Combinations | ACT DORZOTIMOLOL · AG-DORZOLAMIDE TIMOLOL · APO-BRIMONIDINE-TIMOP · APO-DORZO-TIMOP · +43 more | 50 | 21 | Yes |
| Timolol | APO-TIMOP · APO-TIMOP GEL · BETA-TIM - 0.25% LIQ · BETA-TIM - 0.5% LIQ · +20 more | 35 | 7 | Yes |
| Levobunolol | APO-LEVOBUNOLOL OPHTHALMIC SOLUTION USP 0.25% · APO-LEVOBUNOLOL OPHTHALMIC SOLUTION USP 0.5% · BETAGAN 0.5% OPHTHALMIC SOL · BETAGAN OPH SOLN 0.25% · +6 more | 16 | 0 | Not in Canada |
| Betaxolol | BETOPTIC LIQ · BETOPTIC S · NOVO-BETAXOLOL · SANDOZ BETAXOLOL | 4 | 0 | Not in Canada |
| Betaxolol, Combinations | BETOPTIC/PILO | 1 | 0 | Not in Canada |
| Levobunolol, Combinations | PROBETA - LIQ OPH | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC S01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| S01EE | Bimatoprost · Latanoprost · Latanoprostene Bunod · Tafluprost · Travoprost · +1 more | 40 | 19 |
| S01EA | Apraclonidine · Brimonidine · Dipivefrine · Epinephrine | 28 | 10 |
| S01EC | Acetazolamide · Brinzolamide · Brinzolamide, Combinations · Dorzolamide · Methazolamide | 32 | 8 |
| S01EB | Acetylcholine · Carbachol · Ecothiopate · Pilocarpine · Pilocarpine, Combinations | 65 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.